SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

September 28, 2016 07:00 ET

CTD Holdings Presents on Clinical Trials at Niemann-Pick UK Conferences

Company Hosted Second Meeting of Its Family and Physicians Listening Circle

ALACHUA, FL--(Marketwired - September 28, 2016) - CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that the company made presentations on its US and UK clinical studies at both the 7th Interactive Workshop on Niemann-Pick Diseases, and the 23rd Annual Family Conference hosted by Niemann-Pick UK, a non-profit charity in the United Kingdom dedicated to helping families affected by Niemann-Pick Type C (NPC) disease. The presentations were made at meetings held September 16-18, 2016 in Bedfordshire, England.

At the 7th Interactive Workshop on Niemann-Pick Diseases, CTD CEO, N. Scott Fine, and Senior Vice President for Medical Affairs, Dr. Sharon Hrynkow, joined by Dr. Caroline Hastings, UCSF Benioff Children's Hospital Oakland, provided data on the compassionate use of Trappsol® Cyclo™, CTD's proprietary formulation of hydroxylpropyl beta cyclodextrin, in NPC patients, and described CTD's two approved trials for the intravenous administration of Trappsol® Cyclo™. This was the first full presentation of parameters for both the phase I trial in the US, for which Dr. Hastings is the PI, and the phase I/II trial in the UK and EU, for which Dr. Reena Sharma, Salford Royal NHS Foundation Trust is the coordinating PI. This presentation was attended by physicians and scientists from the UK and internationally.

The same team, joined by Professor Alan Boyd, a senior advisor to the company and CEO of Alan Boyd Consultants, made a similar presentation to families and caregivers of NPC patients as part of the 23rd Annual Family Conference of NPUK on September 17. That same day, CTD convened its 2nd meeting of the Family and Physicians Listening Circle, held in conjunction with Niemann-Pick UK. This meeting was open to all families attending the conference. Listening Circle Co-Chair Sue French, parent of an NPC affected child, moderated the discussion which was joined by independent experts and leaders in the NPC and lysosomal storage disease area, including Professor Frances Platt, Oxford University and Dr. Marc Patterson, Mayo Clinic. Families, physicians and scientists shared insights and information on several widely used supplements, such as curcumin, and discussed whether any benefits have been quantified for NPC patients from supplement use. The CTD Listening Circle is a platform for learning and sharing among families, physicians, and the company on a range of topics determined by Listening Circle members.

About the Company:
CTD Holdings, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company's website: www.ctd-holdings.com

Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information